OBJECTIVES: To analyse the effect of biological agents (BAs) in terms of achieving @entity66 ( @entity66 ) or clinical remission (CR) in @entity1 with @entity4932 ( @entity4932 ), to describe effects of switching or discontinuing a BA and to assess the proportion of @entity1 able to maintain @entity66 or CR off @entity230 and after withdrawing BA therapy. METHODS: Retrospective study in a French paediatric rheumatology reference centre using the CEMARA (CEntre des MAladies RAres) register. RESULTS: Seventy-seven @entity1 were included with a cumulative follow-up of 245.5 @entity1 -years (median 1.1, range 0.5-8.0). On a first BA, @entity66 was achieved in 37 @entity1 , including 1 @entity1 out of 12 @entity1 on etanercept, 26 @entity1 out of 51 on anakinra and 7 out of 10 on canakinumab. One @entity1 on abatacept and two @entity1 on tocilizumab also achieved @entity66 . Switching of BA was common. The switch to a second (n=34), third (n=18) or fourth (n=4) BA resulted in @entity66 in a further 13 @entity1 , either on canakinumab (n=6) or tocilizumab (n=7). At last follow-up, 40 @entity1 were in CR (27 @entity1 off @entity230 , 5 @entity1 having never received @entity479 treatment), either on (n=29) or off (n=11) BA. CONCLUSIONS: In this series of @entity1 with @entity4932 , interleukin-1 inhibitors were associated with a higher proportion of @entity66 than @entity5 @entity39 factor inhibitors when used as first BA. Switching allowed some @entity1 to achieve @entity66 when treated with canakinumab or tocilizumab. CR was eventually achieved in more than half of the @entity1 .

Biological treatment in XXXX : achievement of @entity66 or clinical remission on a first, second or third biological agent.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity66 :: ('MESH:D004194', 'Disease') :: ['inactive disease', 'ID'] @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour'] @entity4932 :: ('MESH:D001171', 'Disease') :: ['SJIA', 'systemic juvenile idiopathic arthritis'] @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids'] @entity479 :: ('D013256', 'Chemical') :: ['steroid']
@entity4932 :: (MESH:D001171,Disease) :: ['systemic juvenile idiopathic arthritis']
